Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Kian Behbakht to Humans

This is a "connection" page, showing publications Kian Behbakht has written about Humans.

 
Connection Strength
  
 
 
0.388
  
  1. Rauh-Hain JA, Brewster WR, Behbakht K. Society of Gynecologic Oncology 2018 Annual Meeting on Women's Cancer: Meeting report. Gynecol Oncol. 2018 11; 151(2):e7-e9.
    View in: PubMed
    Score: 0.017
  2. Behbakht K, Cohn DE, Straughn JM. Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer. Gynecol Oncol. 2018 10; 151(1):4-5.
    View in: PubMed
    Score: 0.017
  3. Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecol Oncol. 2017 12; 147(3):695-704.
    View in: PubMed
    Score: 0.016
  4. Jarrett MJ, V?zquez-Torres A, Frank DN, McCollister BD, Henthorn PK, Ir D, Sheeder J, Guy MS, Anwar HQ, Behbakht K. Influence of Gelatin-Thrombin Matrix Tissue Sealant on Bacterial Colony Formation and Risk of Pelvic Infection. Infect Dis Obstet Gynecol. 2016; 2016:2649708.
    View in: PubMed
    Score: 0.015
  5. Goldstein CL, Susman E, Lockwood S, Medlin EE, Behbakht K. Awareness of symptoms and risk factors of ovarian cancer in a population of women and healthcare providers. Clin J Oncol Nurs. 2015 Apr; 19(2):206-12.
    View in: PubMed
    Score: 0.014
  6. Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K. Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer. Gynecol Oncol. 2012 May; 125(2):451-7.
    View in: PubMed
    Score: 0.011
  7. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Oct; 123(1):19-26.
    View in: PubMed
    Score: 0.011
  8. de la Garza J, Wilson SS, Behbakht K. Total pelvic exenteration with a split-thickness skin graft neovagina, continent orthotopic neobladder and rectal reanastomosis, resulting in no external ostomies and adequate sexual function. Gynecol Oncol. 2009 Nov; 115(2):312-3.
    View in: PubMed
    Score: 0.009
  9. Qamar L, Davis R, Anwar A, Behbakht K. Protein kinase C inhibitor G?6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model. Gynecol Oncol. 2008 Sep; 110(3):425-31.
    View in: PubMed
    Score: 0.009
  10. Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A, Ford HL. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res. 2007 Apr 01; 67(7):3036-42.
    View in: PubMed
    Score: 0.008
  11. Behbakht K, Lynch A, Teal S, Degeest K, Massad S. Social and cultural barriers to Papanicolaou test screening in an urban population. Obstet Gynecol. 2004 Dec; 104(6):1355-61.
    View in: PubMed
    Score: 0.007
  12. Greenwood A, Woodruff ER, Nguyen C, Piper C, Clauset A, Brubaker LW, Behbakht K, Bitler BG. Early Ovarian Cancer Detection in the Age of Fallopian Tube Precursors: A Systematic Review. Obstet Gynecol. 2024 Mar 01; 143(3):e63-e77.
    View in: PubMed
    Score: 0.006
  13. McMellen A, Yamamoto TM, Qamar L, Sanders BE, Nguyen LL, Ortiz Chavez D, Bapat J, Berning A, Post MD, Johnson J, Behbakht K, Nurmemmedov E, Chuong EB, Bitler BG. ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer. Mol Cancer Res. 2023 01 03; 21(1):3-13.
    View in: PubMed
    Score: 0.006
  14. Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. NCCN Guidelines? Insights: Ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw. 2022 09; 20(9):972-980.
    View in: PubMed
    Score: 0.006
  15. Yamamoto TM, Webb PG, Davis DM, Baumgartner HK, Woodruff ER, Guntupalli SR, Neville M, Behbakht K, Bitler BG. Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. Mol Cancer Ther. 2022 04 01; 21(4):647-657.
    View in: PubMed
    Score: 0.006
  16. Behbakht K, Friedman J, Heimler I, Aroutcheva A, Simoes J, Faro S. Role of the vaginal microbiological ecosystem and cytokine profile in the promotion of cervical dysplasia: a case-control study. Infect Dis Obstet Gynecol. 2002; 10(4):181-6.
    View in: PubMed
    Score: 0.005
  17. Behbakht K, Abu-Rustum NR, Lee S, San Juan A, Massad LS. Characteristics and survival of cervical cancer patients managed at adjacent urban public and university medical centers. Gynecol Oncol. 2001 Apr; 81(1):40-6.
    View in: PubMed
    Score: 0.005
  18. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 02 02; 19(2):191-226.
    View in: PubMed
    Score: 0.005
  19. Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res. 2020 12 01; 26(23):6362-6373.
    View in: PubMed
    Score: 0.005
  20. Corr BR, Moroney M, Sheeder J, Eckhardt SG, Sawyer B, Behbakht K, Diamond JR. Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials. Cancer. 2020 10 01; 126(19):4289-4293.
    View in: PubMed
    Score: 0.005
  21. Johnson S, Renz M, Wheeler L, Diver E, Dorigo O, Litkouhi B, Behbakht K, Howitt B, Karam A. Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review. Int J Gynecol Cancer. 2020 08; 30(8):1118-1123.
    View in: PubMed
    Score: 0.005
  22. Guntupalli SR, Brennecke A, Behbakht K, Tayebnejad A, Breed CA, Babayan LM, Cheng G, Ramzan AA, Wheeler LJ, Corr BR, Lefkowits C, Sheeder J, Matsuo K, Flink D. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. JAMA Netw Open. 2020 06 01; 3(6):e207410.
    View in: PubMed
    Score: 0.005
  23. Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, Behbakht K, Schlaepfer IR, Bitler BG. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression. Mol Cancer Res. 2020 07; 18(7):1088-1098.
    View in: PubMed
    Score: 0.005
  24. Watson ZL, Yamamoto TM, McMellen A, Kim H, Hughes CJ, Wheeler LJ, Post MD, Behbakht K, Bitler BG. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clin Epigenetics. 2019 11 27; 11(1):165.
    View in: PubMed
    Score: 0.005
  25. O'Cearbhaill RE, Deng W, Chen LM, Lucci JA, Behbakht K, Spirtos NM, Muller CY, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Lankes HA, Aghajanian C, Sabbatini PJ. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384)?+ OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):393-399.
    View in: PubMed
    Score: 0.005
  26. Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations. Mol Cancer Ther. 2020 02; 19(2):602-613.
    View in: PubMed
    Score: 0.005
  27. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw. 2019 08 01; 17(8):896-909.
    View in: PubMed
    Score: 0.005
  28. Ramzan AA, Bitler BG, Hicks D, Barner K, Qamar L, Behbakht K, Powell T, Jansson T, Wilson H. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem. 2019 Nov; 461(1-2):37-46.
    View in: PubMed
    Score: 0.005
  29. Adams CL, Dimitrova I, Post MD, Gibson L, Spillman MA, Behbakht K, Bradford AP. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma. Exp Mol Pathol. 2019 10; 110:104284.
    View in: PubMed
    Score: 0.005
  30. Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog. 2019 10; 58(10):1770-1782.
    View in: PubMed
    Score: 0.005
  31. Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, Fisher C, Lefkowits C, Guntupalli SR, Behbakht K, Corr BR. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol. 2019 06; 153(3):517-520.
    View in: PubMed
    Score: 0.005
  32. Breed C, Hicks DA, Webb PG, Galimanis CE, Bitler BG, Behbakht K, Baumgartner HK. Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel. Mol Cancer Res. 2019 03; 17(3):741-750.
    View in: PubMed
    Score: 0.004
  33. Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):e183773.
    View in: PubMed
    Score: 0.004
  34. Ramzan AA, Behbakht K, Corr BR, Sheeder J, Guntupalli SR. Minority Race Predicts Treatment by Non-gynecologic Oncologists in Women with Gynecologic Cancer. Ann Surg Oncol. 2018 Nov; 25(12):3685-3691.
    View in: PubMed
    Score: 0.004
  35. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol. 1998 Aug; 70(2):255-8.
    View in: PubMed
    Score: 0.004
  36. Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor. EBioMedicine. 2017 Nov; 25:50-57.
    View in: PubMed
    Score: 0.004
  37. Zhou K, Spillman MA, Behbakht K, Komatsu JM, Abrahante JE, Hicks D, Schotl B, Odean E, Jones KL, Graner MW, Bemis LT. A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis. Anal Biochem. 2017 11 01; 536:8-15.
    View in: PubMed
    Score: 0.004
  38. Futia GL, Schlaepfer IR, Qamar L, Behbakht K, Gibson EA. Statistical performance of image cytometry for DNA, lipids, cytokeratin, & CD45 in a model system for circulation tumor cell detection. Cytometry A. 2017 07; 91(7):662-674.
    View in: PubMed
    Score: 0.004
  39. Guntupalli SR, Sheeder J, Ioffe Y, Tergas A, Wright JD, Davidson SA, Behbakht K, Flink DM. Sexual and Marital Dysfunction in Women With Gynecologic Cancer. Int J Gynecol Cancer. 2017 03; 27(3):603-607.
    View in: PubMed
    Score: 0.004
  40. Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, Porter CC, Tan AC, Thorburn A, Ford HL. A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Mol Cancer Res. 2017 04; 15(4):382-394.
    View in: PubMed
    Score: 0.004
  41. Behbakht K, Benjamin I, Chiu HC, Eck SL, Van Deerlin PG, Rubin SC, Boyd J. Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. Am J Obstet Gynecol. 1996 Nov; 175(5):1260-5.
    View in: PubMed
    Score: 0.004
  42. Hicks DA, Galimanis CE, Webb PG, Spillman MA, Behbakht K, Neville MC, Baumgartner HK. Claudin-4 activity in ovarian tumor cell apoptosis resistance and migration. BMC Cancer. 2016 10 11; 16(1):788.
    View in: PubMed
    Score: 0.004
  43. Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM. Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy. Brachytherapy. 2016 Nov - Dec; 15(6):845-850.
    View in: PubMed
    Score: 0.004
  44. Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM. Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer. Gynecol Oncol. 2016 Nov; 143(2):319-325.
    View in: PubMed
    Score: 0.004
  45. Osborne RJ, Filiaci VL, Schink JC, Mannel RS, Behbakht K, Hoffman JS, Spirtos NM, Chan JK, Tidy JA, Miller DS. Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. Obstet Gynecol. 2016 Sep; 128(3):535-542.
    View in: PubMed
    Score: 0.004
  46. Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 09; 14(9):1134-63.
    View in: PubMed
    Score: 0.004
  47. Blake EA, Sheeder J, Behbakht K, Guntupalli SR, Guy MS. Factors Impacting Use of Robotic Surgery for Treatment of Endometrial Cancer in the United States. Ann Surg Oncol. 2016 10; 23(11):3744-3748.
    View in: PubMed
    Score: 0.004
  48. Behbakht K, DeGeest K, Turyk ME, Wilbanks GD. All-trans-retinoic acid inhibits the proliferation of cell lines derived from human cervical neoplasia. Gynecol Oncol. 1996 Apr; 61(1):31-9.
    View in: PubMed
    Score: 0.004
  49. Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Apr; 141(1):43-8.
    View in: PubMed
    Score: 0.004
  50. Behbakht K, Massad LS, Yordan EL, Lincoln SH, Eriksson JA, Winkelman L, DeGeest K, Kirschner C, Wilbanks GD. A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers. Eur J Gynaecol Oncol. 1996; 17(1):7-12.
    View in: PubMed
    Score: 0.004
  51. Guy MS, Qamar L, Behbakht K, Post MD, Sheeder J, Sartorius CA, Spillman MA. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer. Gynecol Oncol. 2016 Mar; 140(3):518-26.
    View in: PubMed
    Score: 0.004
  52. Guy MS, Sheeder J, Behbakht K, Wright JD, Guntupalli SR. Comparative outcomes in older and younger women undergoing laparotomy or robotic surgical staging for endometrial cancer. Am J Obstet Gynecol. 2016 Mar; 214(3):350.e1-350.e10.
    View in: PubMed
    Score: 0.004
  53. Doo DW, Guy MS, Behbakht K, Davidson SA, Sheeder J, Guntupalli SR. Association Between Preoperative Chemotherapy and Postoperative Complications in Patients Undergoing Surgery for Ovarian Cancer. Ann Surg Oncol. 2016 Mar; 23(3):968-74.
    View in: PubMed
    Score: 0.004
  54. Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2015 Nov; 25(9):1565-73.
    View in: PubMed
    Score: 0.004
  55. Zighelboim I, Ali S, Lankes HA, Backes F, Moore K, Mutch D, Robison K, Behbakht K, Waggoner S, Ghebre RG, Pearl M, Ramirez NC, Goodfellow P. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138(3):614-9.
    View in: PubMed
    Score: 0.003
  56. Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015 Apr 01; 33(10):1180-5.
    View in: PubMed
    Score: 0.003
  57. Doo DW, Guntupalli SR, Corr BR, Sheeder J, Davidson SA, Behbakht K, Jarrett MJ, Guy MS. Comparative Surgical Outcomes for Endometrial Cancer Patients 65 Years Old or Older Staged With Robotics or Laparotomy. Ann Surg Oncol. 2015 Oct; 22(11):3687-94.
    View in: PubMed
    Score: 0.003
  58. Behbakht K, Yordan EL, Casey C, DeGeest K, Massad LS, Kirschner CV, Wilbanks GD. Prognostic indicators of survival in advanced endometrial cancer. Gynecol Oncol. 1994 Dec; 55(3 Pt 1):363-7.
    View in: PubMed
    Score: 0.003
  59. Anderson CK, Medlin E, Ferriss AF, Sheeder J, Davidson S, Gibbs R, Behbakht K, Guntupalli SR. Association between gelatin-thrombin matrix use and abscesses in women undergoing pelvic surgery. Obstet Gynecol. 2014 Sep; 124(3):589-595.
    View in: PubMed
    Score: 0.003
  60. Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, Behbakht K, Huh WK. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2014 Jun; 133(3):433-8.
    View in: PubMed
    Score: 0.003
  61. Kim Y, Guntupalli SR, Lee SJ, Behbakht K, Theodorescu D, Lee JK, Diamond JR. Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. PLoS One. 2014; 9(2):e86532.
    View in: PubMed
    Score: 0.003
  62. Guy MS, Cheng G, Post MD, Spillman MA, Behbakht K, Davidson S, Sheeder J, Guntupalli SR. Outcomes of women with atypical glandular cells on preoperative cytology and endometrial cancer. Int J Gynecol Cancer. 2014 Feb; 24(2):266-71.
    View in: PubMed
    Score: 0.003
  63. Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman MA. Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer. 2013 Mar; 23(3):417-21.
    View in: PubMed
    Score: 0.003
  64. Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer. 2013 Jan; 49(1):121-31.
    View in: PubMed
    Score: 0.003
  65. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene. 2013 Mar 14; 32(11):1341-50.
    View in: PubMed
    Score: 0.003
  66. Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, Kelly MG. Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer. 2011 Nov; 21(8):1422-7.
    View in: PubMed
    Score: 0.003
  67. Wang Y, Sheng Q, Spillman MA, Behbakht K, Gu H. Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene. 2012 May 17; 31(20):2512-20.
    View in: PubMed
    Score: 0.003
  68. Dinges MM, Jaggessarsingh D, Petersen TH, Behbakht K, Singh M. Lobular endocervical glandular hyperplasia with extensive mucinous differentiation of endometrium and endometrial mucinous adenocarcinoma in situ: a case report and review of literature. Gynecol Oncol. 2011 Sep; 122(3):686-8.
    View in: PubMed
    Score: 0.003
  69. Menke C, Bin L, Thorburn J, Behbakht K, Ford HL, Thorburn A. Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. Cancer Res. 2011 Mar 01; 71(5):1883-92.
    View in: PubMed
    Score: 0.003
  70. Menke C, Goncharov T, Qamar L, Korch C, Ford HL, Behbakht K, Thorburn A. TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro. PLoS One. 2011 Jan 14; 6(1):e14527.
    View in: PubMed
    Score: 0.003
  71. Ghamande SA, Silverman MH, Huh W, Behbakht K, Ball G, Cuasay L, W?rtz SO, Brunner N, Gold MA. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008 Oct; 111(1):89-94.
    View in: PubMed
    Score: 0.002
  72. Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat. 2008 Feb-Apr; 11(1-2):17-24.
    View in: PubMed
    Score: 0.002
  73. Lyle P, Evans R, Jarboe E, Fong D, Behbakht K, Davidson S, Singh M. Biphasic tumors of the female genital tract. Oncology (Williston Park). 2005 Aug; 19(9):1178, 1183, 1188, 1190, 1195-6 passim.
    View in: PubMed
    Score: 0.002
  74. Massad LS, Behbakht K, Collins YC, Cejtin HE. Histologic findings from the cervix among older women with abnormal cervical cytology. Gynecol Oncol. 2003 Mar; 88(3):340-4.
    View in: PubMed
    Score: 0.001
  75. Anderson J, Behbakht K, De Geest K, Bitterman P. Adenosarcoma in a patient with vaginal endometriosis. Obstet Gynecol. 2001 Nov; 98(5 Pt 2):964-6.
    View in: PubMed
    Score: 0.001
  76. van der Heijden O, Chiu HC, Park TC, Takahashi H, LiVolsi VA, Risinger JI, Barrett JC, Berchuck A, Evans AC, Behbakht K, Menzin AW, Liu PC, Benjamin I, Morgan MA, King SA, Rubin SC, Boyd J. Allelotype analysis of uterine leiomyoma: localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q. Mol Carcinog. 1998 Dec; 23(4):243-7.
    View in: PubMed
    Score: 0.001
  77. Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, Boyd J. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998 Apr; 178(4):670-7.
    View in: PubMed
    Score: 0.001
  78. Bandera CA, Takahashi H, Behbakht K, Liu PC, LiVolsi VA, Benjamin I, Morgan MA, King SA, Rubin SC, Boyd J. Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma. Cancer Res. 1997 Feb 01; 57(3):513-5.
    View in: PubMed
    Score: 0.001
  79. Morgan MA, Behbakht K, Benjamin I, Berlin M, King SA, Rubin SC. Racial differences in survival from gynecologic cancer. Obstet Gynecol. 1996 Dec; 88(6):914-8.
    View in: PubMed
    Score: 0.001
  80. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, Berchuck A, Muto MG, Garber JE, Weber BL, Lynch HT, Boyd J. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 1996 Nov 07; 335(19):1413-6.
    View in: PubMed
    Score: 0.001
  81. Takahashi H, Chiu HC, Bandera CA, Behbakht K, Liu PC, Couch FJ, Weber BL, LiVolsi VA, Furusato M, Rebane BA, Cardonick A, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC, Boyd J. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res. 1996 Jun 15; 56(12):2738-41.
    View in: PubMed
    Score: 0.001
  82. Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, Weber BL, Friedman LS, King MC, Furusato M, LiVolsi VA, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 1995 Jul 15; 55(14):2998-3002.
    View in: PubMed
    Score: 0.001
  83. King SA, Adas AA, LiVolsi VA, Takahashi H, Behbakht K, McGovern P, Benjamin I, Rubin SC, Boyd J. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer. 1995 Jun 01; 75(11):2700-5.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)